Navigation Links
Bayer Consumer Care Launches Citracal(R) Calcium Plus Heart Health, First-Ever Leading Calcium Supplement to Help Support Bone AND Heart Health
Date:11/5/2009

MORRISTOWN, N.J., Nov. 5 /PRNewswire/ -- Bone strength and heart health are two of the most important health issues for women. One out of every two women will have an osteoporosis-related fracture in her lifetime and more than 50 million women have blood cholesterol levels high enough to pose a risk for heart disease. Now there is a new product available to help address both of these issues at the same time. Citracal® Calcium plus Heart Health is the first and only leading calcium supplement that helps support both bone and heart health every day.*

"Calcium and vitamin D are critical for bone health, yet most women aren't always getting enough of these important nutrients," said Julie Upton, MS, RD. "I'm excited that women now have a new option that helps ensure they get enough calcium and vitamin D, as well as natural plant sterols, which may help to reduce their risk of heart disease, the No. 1 killer of women."

New Citracal Calcium plus Heart Health contains 1,260 mg of calcium per daily dose, more than any other leading brand, and has an advanced levels of vitamin D to support calcium absorption.* It also contains Phytosterols, a natural plant ingredient that may reduce the risk of heart disease by lowering cholesterol. +

"We strive to continue to develop new and innovative products to meet our consumers' changing concerns," says Angela Vann, Senior Brand Manager - Citracal. "Women need to attend to bone and heart health daily, and this product conveniently allows them to address both of these important health issues at the same time."

New Citracal plus Heart Health is available at food, mass and drug retail outlets nationwide. For more information visit www.Citracal.com.

About Citracal®

Citracal® has earned the recognition and respect of the medical community, and many physicians recommend Citracal for supplemental calcium. All of the Citracal products contain both calcium and vitamin D. The success of Citracal as a trusted brand has paved the way for adding exciting products to the Citracal line, such as Citracal® Calcium plus Heart Health and Citracal® Plus Bone Density Builder, in addition to Citracal® Maximum, Citracal® Petites, Citracal® Plus with Magnesium and Citracal® Regular. www.citracal.com.

About Bayer Consumer Care

The Consumer Care division of Bayer HealthCare, is headquartered in Morristown, New Jersey, USA. Bayer Consumer Care is among the largest marketers of over-the-counter medications and nutritional supplements in the world. Some of the most trusted and recognizable brands in the world today come from the Bayer portfolio of products. These include Aspirin, ALEVE®, Alka-Seltzer®, Midol®, One A Day® Vitamins, and Flintstones(TM) vitamins.

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma and as Bayer HealthCare Pharmaceuticals in the US and Canada. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

+ Dietary supplements or food containing at least 400mg per serving of free phytosterols, eaten twice a day with meals for a daily total intake of at least 800mg, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease by lowering blood cholesterol. Each Citracal Plus Heart Health Tablet contains 200mg of free phytosterols. This product is not a replacement for cholesterol-lowering medications.

SOURCE Bayer Consumer Care


'/>"/>
SOURCE Bayer Consumer Care
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
Breaking Medicine Technology:
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):